Sustained release of papaverine for the treatment of cerebral vasospasm: in vitro evaluation of release kinetics and biological activity. J Neurosurg 1992 Nov;77(5):783-7
Date
11/01/1992Pubmed ID
1403123DOI
10.3171/jns.1992.77.5.0783Scopus ID
2-s2.0-0026730136 (requires institutional sign-in at Scopus site) 15 CitationsAbstract
Cerebral vasospasm remains an unpredictable and inadequately treated complication of aneurysmal subarachnoid hemorrhage. To date, pharmacological treatment has been plagued in part by an inability to attain sufficiently high concentrations of vasodilator drug in the cerebrospinal fluid without precipitating systemic side effects such as hypotension. To circumvent this limitation of current pharmacological therapy, the authors have developed a sustained-release preparation of papaverine that can be implanted intracranially at the time of surgery for aneurysm clipping. In vitro evaluation of drug-release kinetics has demonstrated that reliable, sustained release of effective amounts of papaverine is possible. An in vitro bioassay using isolated preparations of canine basilar artery has confirmed the biological activity of this preparation. These in vitro studies are described.
Author List
Heffez DS, Leong KWAuthor
Dan S. Heffez MD Professor in the Neurosurgery department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
AnimalsBasilar Artery
Delayed-Action Preparations
Dogs
Drug Implants
In Vitro Techniques
Ischemic Attack, Transient
Papaverine